ARTICLE | Finance
Disarm and derisk
Disarm’s journey from Atlas seedling to $30M series A
September 22, 2017 4:59 AM UTC
After replicating the effect of sterile alpha and TIR motif containing 1 gene knockout with small molecule SARM1 inhibitors, axon degeneration company Disarm Therapeutics Inc. passed the milestone needed to unlock series A funding from seed investor Atlas Venture.
New investors Lightstone Ventures and AbbVie Ventures also participated in the $30 million A round, which closed on Sept. 19. ...
BCIQ Target Profiles